JPMA Enhances Policy Lobbying Efforts
This article was originally published in PharmAsia News
The Japan Pharmaceutical Manufacturer’s Association is stepping up policy advocacy campaigns to get its message out to policy makers in Japan, said JPMA’s new director of public affairs Akira Fujii.
You may also be interested in...
The sentences are the latest chapter in a long-running off-label marketing case.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.